Senior Scientist, Dmpk

Overview
The successful candidate will be part of a team working on determining the disposition mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) relationships of oligonucleotides. The candidate will work closely with colleagues in Research and Development, as a Senior Director of drug metabolism and pharmacokinetics (DMPK).
Key Responsibilities
• Develop and execute DMPK strategies and plans aligned with the platform, programs, and company goals to achieve strong discovery piplelines and successful worldwide registration of Alnylam drugs

• Collaborate with scientists and project leaders in Research to enhance siRNA delivery to targeted tissues, enable drug candidate selection, characterization, and transition into development
• Partner with Research, Toxicology, and Clinical Pharmacology teams to apply model-based approaches in PK/PD/safety data integrations to inform clinical development plans
• Represent DMPK on a variety of interdisciplinary teams
• Ensure the delivery of all reports and appropriate sections of regulatory documents to support INDs, NDAs, and other worldwide regulatory dossiers

Qualifications

• Ph.D. in pharmacokinetics, pharmaceutical sciences, or related disciplines
• In-depth knowledge and understanding of pharmacokinetic and PK/PD principles
• Proficient in model-based data integration, analysis and projection.
• Three plus years of experience in the pharmaceutical industry
• Proven track record of problem-solving and employing modeling and simulation for data integration
• Excellent interpersonal, written, and oral communication skills
• Experience with oligonucleotide-based therapeutics, molecular biology, and genetics is preferred, or the candidate must have experience with multiple drug modalities

About Alnylam
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.
Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Alnylam is an E-Verify employer.